Statistik Asas
| LEI | 52990044IHUOUMETT163 |
| CIK | 899923 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Myriad Genetics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 18, 2025 |
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer Exhibit 99.1 Myriad Genetics Appoints Ben Wheeler Chief Financial Officer SALT LAKE CITY, August 18, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 20 |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENET |
|
| August 6, 2025 |
Exhibit 10.4 MYRIAD GENETICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective: June 2025) The following is a description of the standard compensation arrangements under which the non-employee directors of Myriad Genetics, Inc. (the “Company,” “our” or “we”) are compensated for their service as directors of the Company, including as members of the various committees of our Board of Direct |
|
| August 5, 2025 |
Exhibit 99.1 Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum Highlights •Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year. •Second quarter 2025 hereditary cancer testing revenue and volume in Onc |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| July 31, 2025 |
Myriad Genetics Announces New $200 Million Credit Facility Exhibit 99.1 Myriad Genetics Announces New $200 Million Credit Facility SALT LAKE CITY, July 31, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed, a leading global healthcare investment firm. The facilit |
|
| July 31, 2025 |
Exhibit 10.2 PLEDGE AND SECURITY AGREEMENT This PLEDGE AND SECURITY AGREEMENT, dated as of July 31, 2025 (as amended, supplemented or otherwise modified from time to time, this “Security Agreement”), is made by MYRIAD GENETICS, INC., a Delaware corporation (the “Borrower”), and the other entities listed on Annex A hereto (together with the Borrower and any other entity that may become party hereto |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| July 31, 2025 |
Exhibit 10.1 CREDIT AGREEMENT dated as of July 31, 2025 by and among MYRIAD GENETICS, INC., as the Borrower, ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as the Initial Lender, and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as the Administrative Agent TABLE OF CONTENTS Page SECTION 1.1 Defined Terms. 1 SECTION 1.2 Use of Defined Terms 31 SECTION 1.3 Cross-References 31 SECTION 1.4 Accounting |
|
| June 5, 2025 |
Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended. MYRIAD GENETICS, INC. 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN AS AMENDED (June 5, 2025) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended, have the following meanings: Administrator means the Board of Directors, |
|
| June 5, 2025 |
Calculation of Filing Fee Tables S-8 MYRIAD GENETICS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, par value $0. |
|
| June 5, 2025 |
2017 Employee, Director and Consultant Equity Incentive Plan, as amended MYRIAD GENETICS, INC. 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN AS AMENDED (June 5, 2025) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended, have the following meanings: Administrator means the Board of Directors, |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 5, 2025 |
As filed with the Securities and Exchange Commission on June 5, 2025 As filed with the Securities and Exchange Commission on June 5, 2025 REGISTRATION NO. |
|
| May 7, 2025 |
, dated May 1, 2025, by and between t MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Time-Based) 1. Name of Participant: Brian Donnelly 2. Grant Date: May 1, 2025 3. Vesting Start Date: May 1, 2025 4. Number of Restricted Stock Units (“RSUs”) Awarded: 269,905 5. Vesting Schedule: This Award shall vest as follows provided the Participant is an Employee of, or providing services to, the Company or of an Affiliate on the appli |
|
| May 7, 2025 |
Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Performance-Based) 1. Name of Participant: Brian Donnelly 2. Grant Date: May 1, 2025 3. Vesting Start Date: May 1, 2025 4. Number of Restricted Stock Units (“RSUs”) Awarded: 236,167 5. Vesting Schedule: This Award shall vest on the date of certification by the Administrator of the Achievement (as defined below) of the following milestone st |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENE |
|
| May 6, 2025 |
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Exhibit 99.1 Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Highlights •First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year. •First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to Un |
|
| May 6, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 1, 2025 |
Calculation of Filing Fee Tables S-8 MYRIAD GENETICS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0. |
|
| May 1, 2025 |
Form of Performance-Based Restricted Stock Unit Agreement MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Performance-Based) 1. Name of Participant: Brian Donnelly 2. Grant Date: May 1, 2025 3. Vesting Start Date: May 1, 2025 4. Number of Restricted Stock Units (“RSUs”) Awarded: 236,167 5. Vesting Schedule: This Award shall vest on the date of certification by the Administrator of the Achievement (as defined below) of the following milestone st |
|
| May 1, 2025 |
Form of Restricted Stock Unit Agreement MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Time-Based) 1. Name of Participant: Brian Donnelly 2. Grant Date: May 1, 2025 3. Vesting Start Date: May 1, 2025 4. Number of Restricted Stock Units (“RSUs”) Awarded: 269,905 5. Vesting Schedule: This Award shall vest as follows provided the Participant is an Employee of, or providing services to, the Company or of an Affiliate on the appli |
|
| May 1, 2025 |
As filed with the Securities and Exchange Commission on May 1, 2025 As filed with the Securities and Exchange Commission on May 1, 2025 REGISTRATION NO. |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 28, 2025 |
Exhibit 10.6.1 LEASE AGREEMENT This Lease Agreement (the "Lease") is made and entered into effective on the 1st day of December, 2012, (the "Effective Date") by and between the City of Mason, Ohio, an Ohio municipal corporation, 6000 Mason-Montgomery Road, Mason, Ohio 45040 (hereinafter referred to as "Lessor") and AssureRx Health, Inc., a Delaware Corporation, 6030 S. Mason Montgomery Road, Mason |
|
| February 28, 2025 |
Exhibit 10.6.2 FIFTH ADDENDUM TO ASSUREX HEALTH, INC. LEASE AGREEMENT AT 6000 MASON-MONTGOMERY ROAD This Fifth Addendum to Lease Agreement (“Fifth Addendum”) is dated this 20th day of February, 2025 and shall be effective commencing April 1, 2025 between Assurex Health, Inc., a Delaware corporation (“Lessee” and also referred to herein as “Myriad”) and the City of Mason, Ohio, a political subdivis |
|
| February 28, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC. Company Name Jurisdiction of Incorporation Myriad Genetic Laboratories, Inc.1 Delaware Assurex Health, Inc.1 Delaware Crescendo Bioscience, LLC2 Delaware Gateway Genomics, LLC1 Delaware Myriad Women’s Health, Inc1 Delaware Myriad GmbH3 Germany Myriad Genetics GmbH 3 Switzerland Myriad Genetics B.V.1 Netherlands Myriad Genetics GK1 Japan 1 |
|
| February 28, 2025 |
Exhibit 19 Purpose The Board of Directors (the “Board”) of Myriad Genetics, Inc. (together with its direct and indirect subsidiaries, the “Company”) has adopted this Insider Trading Policy (this “Policy”), effective as of February 13, 2025. Scope This Policy applies to all trading or other transactions involving or related to Company securities (such as common stock, preferred stock, options to bu |
|
| February 28, 2025 |
Exhibit 10.4.2 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this “Amendment”) is dated as of this 10th day of April, 2024 (the “Amendment Date”), by and between ATP SLC D, LLC, a Delaware limited liability company (“Lessor”), and MYRIAD GENETICS, INC., a Delaware corporation (“Lessee”). Recitals A.Lessee and Lessor are parties to that certain Lease, dated for reference purposes only a |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| February 24, 2025 |
Severance and Change of Control Agreement, dated February 2 Exhibit 10.4 SEVERANCE AND CHANGE OF CONTROL AGREEMENT This Severance and Change of Control Agreement (the “Agreement”) is made and entered into on February 24, 2025, by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Mark S. Verratti (“Employee”). WHEREAS, Employee and the Company previously entered into a Severance and Change of Control Agreement dated October 9, 2 |
|
| February 24, 2025 |
, 2025, by and between the Company and Mark S. Verratti. Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 24th day of February, 2025 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Mark S. Verratti (“Executive”). WHEREAS, Executive currently is employed by Company as its Chief Commercial Officer; WHEREAS, following the r |
|
| February 24, 2025 |
Exhibit 99.1 News Release Media Contact: Kate Schraml Investor Contact: Matt Scalo (224) 875-4493 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth Highlights •Fourth quarter 2024 revenue of $211 mil |
|
| February 24, 2025 |
, 2025, by and between the Company and Paul J. Diaz. Exhibit 10.5 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”) is entered into effective as of April 30, 2025 (the “Effective Date”), between Myriad Genetics, Inc. (the “Company”), with a business address at 322 North 2200 West Salt Lake City, Utah 84116, and Paul J. Diaz (the “Consultant”), and governs the Consultant’s services provided to the Company and any of its affiliates as a |
|
| February 24, 2025 |
Exhibit 99.2 News Release Myriad Genetics Announces Senior Leadership Transition Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025 SALT LAKE CITY, February 24, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company’s current Chief Opera |
|
| February 24, 2025 |
Exhibit 10.2 SEVERANCE AND CHANGE OF CONTROL AGREEMENT This Severance and Change of Control Agreement (the “Agreement”) is made and entered into on February 24, 2025, by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Samraat S. Raha (“Employee”). WHEREAS, Employee and the Company previously entered into a Severance and Change of Control Agreement dated December 11, |
|
| February 24, 2025 |
Amended and Restated Employment Agreement, dated February 2 Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement”), made and entered into this 24th day of February, 2025 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Samraat S. Raha (“Executive”). WHEREAS, Executive currently is employed by Company as its Chief Ope |
|
| February 14, 2025 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2025 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 10, 2025 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Myriad Genetics, Inc. |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 15, 2025 |
Exhibit 99.1 News Release Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance SALT LAKE CITY, January 15, 2025 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended Decembe |
|
| December 10, 2024 |
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member Exhibit 99.1 News Release Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member SALT LAKE CITY, December 10, 2024 - Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced the election of Mark S. Davis to its Board of Directors, effective immediately, expanding the Board from eight to nine members. Additionally, Da |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| November 14, 2024 |
MYGN / Myriad Genetics, Inc. / GLENVIEW CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 sc13gano2mygn.htm SC 13G/A 1 sayw2402142513ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Myriad Genetics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 62855J104 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD |
|
| November 7, 2024 |
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance Highlights •Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on pa |
|
| November 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENET |
|
| August 6, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| August 6, 2024 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% Highlights •Second quarter revenue grew 15% year-o |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 3, 2024 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE MYRIAD GENETICS, INC. STOCKHOLDER DERIVATIVE LITIGATION ) ) C.A. No. 2021-0686-SG STIPULATION OF SETTLEMENT This Stipulation of Settlement (“Stipulation”) is made and entered into as of April 30, 2024, between and among, (a)(i) plaintiffs Donna Hickok (“Hickok”) and Leo Shumacher (“Shumacher”) in the above-captioned consolidated derivative ac |
|
| June 3, 2024 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE MYRIAD GENETICS, INC. STOCKHOLDER DERIVATIVE LITIGATION ) ) C.A. No. 2021-0686-SG NOTICE OF PENDENCY OF SETTLEMENT OF DERIVATIVE LITIGATION TO: ALL CURRENT STOCKHOLDERS OF MYRIAD GENETICS, INC. (NASDAQ SYMBOL: MYGN) PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS WILL BE AFFECTED BY THE LEGAL PROCEEDINGS IN THI |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENE |
|
| May 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 7, 2024 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: •First quarter revenue of $2 |
|
| May 1, 2024 |
MYGN / Myriad Genetics, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G 1 MYGNSC13GMay2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYRIAD GENETICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 62855J104 (CUSIP Number) APRIL 25, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designat |
|
| April 25, 2024 |
MYGN / Myriad Genetics, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G 1 MYGNSC13GApril2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYRIAD GENETICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 62855J104 (CUSIP Number) APRIL 17, 2024 (Date of event which requires filing of this statement) Check the appropriate box to design |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| March 18, 2024 |
MYGN / Myriad Genetics, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYRIAD GENETICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 62855J104 (CUSIP Number) MARCH 12, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 28, 2024 |
ease Termination Agreement, dated December 18, 2023, between the R Exhibit 10.1.3 EXECUTION VERSION LEASE TERMINATION AGREEMENT (Myriad Genetics: Phase I) THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is entered into as of the 18th day of December, 2023 (the “Effective Date”) by and between HCPI/UTAH II, LLC, a Delaware limited liability company (“Landlord”) and MYRIAD GENETICS, INC., a Delaware corporation (“Tenant”) (each a “Party” and collectively the “P |
|
| February 28, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC. Company Name Jurisdiction of Incorporation Myriad Genetic Laboratories, Inc.1 Delaware Assurex Health, Inc.1 Delaware Crescendo Bioscience, LLC2 Delaware Gateway Genomics, LLC1 Delaware Myriad Women’s Health, Inc1 Delaware Myriad GmbH4 Germany Myriad Services GmbH3 Germany Myriad Genetics Espana SL1 Spain Myriad Genetics SAS3 France Myriad |
|
| February 28, 2024 |
dated February 9, 2022, between Myriad Genetics, Inc. and Bay Bridge/Corporate, LLC. Exhibit 10.4 Building D LEASE 322 North 2200 West (Building D) Salt Lake City, Utah LESSOR: BAY BRIDGE/CORPORATE, LLC LESSEE: MYRIAD GENETICS, INC. Building D TABLE OF CONTENTS Page Section 1 PARTIES 1 Section 2 PREMISES 1 2.1 Premises 1 2.2 Common Areas 3 Section 3 TERM 6 3.1 Term 6 3.2 Termination Right 7 Section 4 RENT 7 4.1 Monthly Basic Rent 7 4.2 Additional Charges 8 4.3 Net Lease 9 Section |
|
| February 28, 2024 |
Exhibit 10.17 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 15th day of December, 2023 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Scott Leffler (“Executive”). WHEREAS, the Company wishes to employ Executive as its Chief Financial Officer; WHEREAS, Executive represents t |
|
| February 28, 2024 |
ration and Consulting Agreement and Release of Claims, dated December 15, 2023 Exhibit 10.18 SEPARATION AND CONSULTING AGREEMENT AND RELEASE OF CLAIMS This Separation and Consulting Agreement and Release of Claims (“Agreement”), dated as of December 15, 2023, is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and R. Bryan Riggsbee (“Executive” and together with the Company, the “Parties” an |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| February 28, 2024 |
Exhibit 10.3.3 EXECUTION VERSION LEASE TERMINATION AGREEMENT (Myriad Genetics: Phase III) THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is entered into as of the 18th day of December, 2023 (the “Effective Date”) by and between HCPI/UTAH II, LLC, a Delaware limited liability company (“Landlord”) and MYRIAD GENETICS, INC., a Delaware corporation (“Tenant”) (each a “Party” and collectively the |
|
| February 28, 2024 |
ease Termination Agreement, dated December 18, 2023, between Exhibit 10.2.3 EXECUTION VERSION LEASE TERMINATION AGREEMENT (Myriad Genetics: Phase II) THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is entered into as of the 18th day of December, 2023 (the “Effective Date”) by and between HCPI/UTAH II, LLC, a Delaware limited liability company (“Landlord”) and MYRIAD GENETICS, INC., a Delaware corporation (“Tenant”) (each a “Party” and collectively the “ |
|
| February 28, 2024 |
, by and between Myriad Genetics, Inc. and Samraat S. Raha+ Exhibit 10.16 SEVERANCE AND CHANGE OF CONTROL AGREEMENT This Severance and Change of Control Agreement (the “Agreement”) is made and entered into on December 11, 2023 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Samraat S. Raha (“Employee”). WHEREAS, Employee is currently employed by the Company under the terms of a separate employment a |
|
| February 28, 2024 |
Exhibit 97.1 CLAWBACK POLICY I.Introduction The Board of Directors (the “Board”) of Myriad Genetics, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this policy |
|
| February 28, 2024 |
etween Myriad Women's Health, Inc. and Bayside Area Development, LLC. Exhibit 10.5 NEXUS ON GRAND LEASE This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between BAYSIDE AREA DEVELOPMENT, LLC, a Delaware limited liability company ("Landlord"), and MYRIAD GENETICS, INC., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE DESCRIPTION 1 |
|
| February 28, 2024 |
Exhibit 10.19 SEPARATION AND CONSULTING AGREEMENT AND RELEASE OF CLAIMS This Separation and Consulting Agreement and Release of Claims (“Agreement”), dated as of October 4, 2023, is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and Nicole Lambert (“Executive” and together with the Company, the “Parties” and eac |
|
| February 27, 2024 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS o |
|
| February 27, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| February 14, 2024 |
EX-1 2 CamberMYGN-13Ga2024ex1.htm JOINT FILLING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2024 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securiti |
|
| February 14, 2024 |
MYGN / Myriad Genetics, Inc. / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment SC 13G/A 1 CamberMYGN13Ga2024.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Myriad Genetics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statem |
|
| February 14, 2024 |
MYGN / Myriad Genetics, Inc. / GLENVIEW CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 sayw2402142513ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Myriad Genetics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the app |
|
| February 13, 2024 |
MYGN / Myriad Genetics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01504-myriadgeneticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Myriad Genetics Inc Title of Class of Securities: Common Stock CUSIP Number: 62855J104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to desig |
|
| February 8, 2024 |
MYGN / Myriad Genetics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Myriad Genetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62855J104 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| January 23, 2024 |
MYGN / Myriad Genetics, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MYRIAD GENETICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 62855J104 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rul |
|
| January 16, 2024 |
©2024 Myriad Genetics, Inc. 42nd Annual J.P. Morgan Healthcare Conference J A N U A R Y 1 0 , 2 0 2 4 ©2024 Myriad Genetics, Inc. ©2024 Myriad Genetics, Inc. Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company. FORWARD-LOOKING STATEMENTS AND DISCLAIMERS These statements are |
|
| January 16, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 21, 2023 |
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance SALT LAKE CITY, Dec. |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| November 13, 2023 |
Exhibit 1.1 Myriad Genetics, Inc. Common Stock Underwriting Agreement November 8, 2023 Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, Wells Fargo Securities, LLC, As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282 c/o Morgan Stanley & Co. LLC, 1585 Broadway New York, New York |
|
| November 13, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) MYRIAD GENETICS, INC. |
|
| November 13, 2023 |
6,470,588 Shares Myriad Genetics, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-275396 Prospectus Supplement (To Prospectus dated November 8, 2023) 6,470,588 Shares Myriad Genetics, Inc. Common Stock We are offering 6,470,588 shares of our common stock, par value $0.01 per share. Our common stock is listed on The Nasdaq Global Select Market under the trading symbol “MYGN.” On November 8, 2023, the last reported sale price |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 9, 2023 |
Myriad Genetics Announces Pricing of Upsized Offering of Common Stock Salt Lake City, Utah, November 8, 2023 – Myriad Genetics, Inc. |
|
| November 8, 2023 |
As filed with the Securities and Exchange Commission on November 8, 2023 As filed with the Securities and Exchange Commission on November 8, 2023 Registration No. |
|
| November 8, 2023 |
Form of Indenture for debt securities between the registrant and the trustee to be named therein. Exhibit 4.3 =================================================================== MYRIAD GENETICS, INC. - INDENTURE Dated as of , - DEBT SECURITIES [ ] Trustee =================================================================== Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.0 |
|
| November 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Myriad Genetics, Inc. |
|
| November 8, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-275396 The information in this preliminary prospectus supplement is not complete and may be changed. Neither this preliminary prospectus supplement nor the accompanying prospectus is an offer to sell these securities nor does it solicit offers to buy these securities in any jurisdiction where such offer or sale is not permitted. Subject to Comp |
|
| November 7, 2023 |
, between Myriad Genetics, Inc. and Samraat S. Raha+ Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 17th day of October, 2023 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Samraat S. Raha (“Executive”). WHEREAS, the Company wishes to employ Executive as its Chief Operating Officer; WHEREAS, Executive represents t |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD |
|
| November 6, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 6, 2023 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance Highlights: •Third quarter testing volume grew 18% year-over-year, exclu |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 1, 2023 |
Press Release, Dated November 1, 2023 Myriad Genetics Appoints Sam Raha as Chief Operating Officer SALT LAKE CITY, Nov. 1, 2023 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023. Raha adds more than 25 years of general management, commercial, and operations experience, deeply rooted in li |
|
| October 31, 2023 |
FIRST AMENDMENT TO CREDIT AGREEMENT AND PLEDGE AND SECURITY AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT AND PLEDGE AND SECURITY AGREEMENT (this “Amendment”), dated as of October 31, 2023, is among MYRIAD GENETICS, INC. |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 17, 2023 |
MYGN / Myriad Genetics, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G 1 MYGNSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MYRIAD GENETICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 62855J104 (CUSIP Number) OCTOBER 10, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 5, 2023 |
Exhibit 10.1 SEPARATION AND CONSULTING AGREEMENT AND RELEASE OF CLAIMS This Separation and Consulting Agreement and Release of Claims (“Agreement”), dated as of October 4, 2023, is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and Nicole Lambert (“Executive” and together with the Company, the “Parties” and each |
|
| August 4, 2023 |
Restated Certificate of Incorporation, as amended mgirestatedcertificateof PAGE 1 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED ARE TRUE AND CORRECT COPIES OF ALL DOCUMENTS FILED FROM AND INCLUDING THE RESTATED CERTIFICATE OR A MERGER WITH A RESTATED CERTIFICATE ATTACHED OF “MYRIAD GENETICS, INC. “ AS RECEIVED AND FILED IN THIS OFFICE. THE FOLLOWING DOCUMENTS HAVE BEEN CERTIFIED: RESTATED CERTI |
|
| August 4, 2023 |
Non-Employee Director Compensation Policy Exhibit 10.4 MYRIAD GENETICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective: June 2023) The following is a description of the standard compensation arrangements under which the non-employee directors of Myriad Genetics, Inc. (the “Company,” “our” or “we”) are compensated for their service as directors of the Company, including as members of the various committees of our Board of Direct |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENET |
|
| August 3, 2023 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth Highlights: •Second quarter t |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| July 6, 2023 |
Exbibit 10.2 PLEDGE AND SECURITY AGREEMENT THIS PLEDGE AND SECURITY AGREEMENT (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”) is entered into as of June 30, 2023 by and among MYRIAD GENETICS, INC., a Delaware corporation (the “Borrower”), MYRIAD GENETICS LABORATORIES, INC., a Delaware corporation, MYRIAD WOMEN’S |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| July 6, 2023 |
Exhibit 10.1 CREDIT AGREEMENT dated as of June 30, 2023 among MYRIAD GENETICS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A. and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Joint Bookrunners and Joint Lead Arrangers ASSET BASED LENDING TABLE OF CONTENTS Page ARTICLE I Definitions 1 SECTION 1.01. Defined Terms 1 SECTION 1.02. Classific |
|
| July 6, 2023 |
myriadgeneticsannouncesn Myriad Genetics Announces New $90 Million Asset-Based Credit Facility SALT LAKE CITY, July 6, 2023 –Myriad Genetics, Inc. |
|
| June 2, 2023 |
Certificate of Amendment to Restated Certificate of Incorporation, as amended, dated June 1, 2023 certificateofamendmentex |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 1, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Myriad Genetics, Inc. |
|
| June 1, 2023 |
As filed with the Securities and Exchange Commission on June 1, 2023 As filed with the Securities and Exchange Commission on June 1, 2023 REGISTRATION NO. |
|
| June 1, 2023 |
2017 Employee, Director and Consultant Equity Incentive Plan, as amended MYRIAD GENETICS, INC. 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN AS AMENDED (June 1, 2023) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended, have the following meanings: Administrator means the Board of Directors, |
|
| May 4, 2023 |
Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan (Employee). MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AGREEMENT - INCORPORATED TERMS AND CONDITIONS This AGREEMENT (the “Agreement”) made as of the date of grant set forth in the Restricted Stock Unit Award Grant Notice between MYRIAD GENETICS, INC. (the “Company”), a Delaware corporation, and the individual whose name appears on the Restricted Stock Unit Award Grant Notice (the “Participant”). WHEREAS, the |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENE |
|
| May 3, 2023 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range Highlig |
|
| May 3, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 12, 2023 |
mygn-20221231xars412 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| March 1, 2023 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC. Company Name Jurisdiction of Incorporation Myriad Genetic Laboratories, Inc.1 Delaware Assurex Health, Inc.1 Delaware Crescendo Bioscience, LLC2 Delaware Gateway Genomics, LLC1 Delaware Myriad Women’s Health, Inc1 Delaware Myriad GmbH4 Germany Myriad Services GmbH3 Germany Myriad Genetics Espana SL1 Spain Myriad Genetics SAS3 France Myriad |
|
| March 1, 2023 |
MYGN / Myriad Genetics, Inc. / GLENVIEW CAPITAL MANAGEMENT, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Myriad Genetics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 62855J104 (CUSIP Number) February 24, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 28, 2023 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes Highlights: •Fourth quarter t |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| February 14, 2023 |
MYGN / Myriad Genetics, Inc. / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment SC 13G/A 1 camberMYGN13Ga2023.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Myriad Genetics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statem |
|
| February 14, 2023 |
EX-1 2 camberMYGN-13Ga2023ex1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2023 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securitie |
|
| February 9, 2023 |
MYGN / Myriad Genetics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01470-myriadgeneticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Myriad Genetics Inc. Title of Class of Securities: Common Stock CUSIP Number: 62855J104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to desi |
|
| February 6, 2023 |
MYGN / Myriad Genetics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Myriad Genetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62855J104 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD |
|
| November 2, 2022 |
Non-Employee Director Compensation Policy+ MYRIAD GENETICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective: September 2022) The following is a description of the standard compensation arrangements under which the non-employee directors of Myriad Genetics, Inc. (the “Company,” “our” or “we”) are compensated for their service as directors of the Company, including as members of the various committees of our Board of Directors (the |
|
| November 1, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 1, 2022 |
Myriad Genetics Reports Third Quarter Financial Results Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Matt Scalo (385) 318-3718 (801) 584-3532 [email protected] [email protected] Myriad Genetics Reports Third Quarter Financial Results Highlights: ?Revenue of $156.4 million for the quarter ended September 30, 2022. ?Third quarter revenue, excluding divested businesses, was impacted by currency translations ($3.3 mil |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENET |
|
| August 4, 2022 |
Myriad Genetics Reports Second Quarter Financial Results Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Foster Harris (385) 318-3718 (385) 350-8015 [email protected] [email protected] Myriad Genetics Reports Second Quarter Financial Results Highlights: ?Revenue of $179.3 million for the quarter ended June 30, 2022 ?Excluding revenue from divested businesses, revenue increased 7% year-over-year and 9% sequentially |
|
| August 4, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| July 27, 2022 |
EXECUTION VERSION AMENDMENT NO. 4 dated as of July 26, 2022 to CREDIT AGREEMENT Dated as of December 23, 2016 THIS AMENDMENT NO. 4 (?Amendment?), dated as of July 26, 2022 (the ?Effective Date?), is entered into by and among MYRIAD GENETICS, INC., a Delaware corporation (the ?Borrower?), the Lenders party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent (the ?Administrative Agent?). |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| June 6, 2022 |
As filed with the Securities and Exchange Commission on June 6, 2022 As filed with the Securities and Exchange Commission on June 6, 2022 REGISTRATION NO. |
|
| June 6, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Myriad Genetics, Inc. |
|
| June 2, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 2, 2022 |
Amended and Restated 2012 Employee Stock Purchase Plan Exhibit 10.1 MYRIAD GENETICS, INC. AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the Amended and Restated 2012 Employee Stock Purchase Plan (the ?Plan?) of Myriad Genetics, Inc. (the ?Company?). 1. Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock o |
|
| May 12, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated May 12, 2022 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| May 12, 2022 |
MYGN / Myriad Genetics, Inc. / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Myriad Genetics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 62855J104 (CUSIP Number) May 02, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENE |
|
| May 5, 2022 |
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022 Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Nathan Smith (315) 730-2379 (801) 505-5067 [email protected] [email protected] Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022 Highlights: ?Revenue of $164.9 million for the quarter ended March 31, 2022 ?Excluding revenue from divested businesses, revenue increased 11% year-over-yea |
|
| May 5, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| February 25, 2022 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC. Company Name Jurisdiction of Incorporation Myriad Genetic Laboratories, Inc.1 Delaware Assurex Health, Inc.1 Delaware Crescendo Bioscience, LLC2 Delaware Myriad Women?s Health, Inc1 Delaware Myriad GmbH4 Germany Myriad Services GmbH3 Germany Myriad Genetics Espana SL1 Spain Myriad Genetics SAS3 France Myriad Genetics S.r.l.1 Italy Myriad G |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENETICS, IN |
|
| February 24, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| February 24, 2022 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Nathan Smith (315) 730-2379 (801) 505-5067 [email protected] [email protected] Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives Highlights: ?Strong business performance despite COVID-19 headwinds ?Revenue of $160.8 million in the fourth quarter an |
|
| February 14, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2022 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 14, 2022 |
MYGN / Myriad Genetics, Inc. / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Myriad Genetics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 10, 2022 |
MYGN / Myriad Genetics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Myriad Genetics Inc. Title of Class of Securities: Common Stock CUSIP Number: 62855J104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 9, 2022 |
Consulting Agreement, dated February 7, 2022, by and between Exhibit 10.1 SEPARATION AND CONSULTING AGREEMENT This Separation and Consulting Agreement (?Agreement?), dated as of February 7, 2022, is entered into between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the ?Company?), and Jerry Lanchbury (?Employee? and, together with the Company, the ?Parties? and each a ?Party?). WHEREAS, Employee is employed by th |
|
| February 4, 2022 |
MYGN / Myriad Genetics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Myriad Genetics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| January 11, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 11, 2022 |
Illuminating the path to better health through genetic insights 40th Annual J.P. Morgan Health Care Conference January 11, 2022 Paul J. Diaz President and CEO Myriad Genetics ?2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com 2 Forward looking statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| December 14, 2021 |
Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer SALT LAKE CITY, Dec. |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| November 4, 2021 |
Amended and Restated 2012 Employee Stock Purchase Plan+ Exhibit 10.1 MYRIAD GENETICS, INC. AMENDED AND RESTATED 2012 EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the Amended and Restated 2012 Employee Stock Purchase Plan (the ?Plan?) of Myriad Genetics, Inc. (the ?Company?). 1. Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock o |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD |
|
| November 2, 2021 |
Exhibit 99.1 News Release Media Contact: Megan Manzari Investor Contact: Nathan Smith (315) 730-2379 (801) 505-5067 [email protected] [email protected] Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans Highlights: ?Revenue of $167.3 million up 15% year-over-year. Excluding revenue from divested businesses, revenue |
|
| November 2, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENET |
|
| August 3, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File |
|
| August 3, 2021 |
Exhibit 99.1 News Release Media Contact: Jared Maxwell Investor Contact: Nathan Smith (801) 505-5027 (801) 505-5067 [email protected] [email protected] Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans SALT LAKE CITY, August 3, 2021 ? Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic tes |
|
| June 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 24, 2021 |
Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions Exhibit 99.1 News Release Media Contact: Jared Maxwell Investor Contact: Nathan Smith (801) 505-5027 (801) 505-5067 [email protected] [email protected] Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions SALT LAKE CITY, May 24, 2021 ? Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitiv |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GENE |
|
| May 3, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 3, 2021 |
Exhibit 99.1 News Release Media Contact: Jared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 [email protected] [email protected] Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives Highlights: ?Revenue of $173.1 million increases 12% sequentially ?GAAP earnings per share of $(0.52), adjus |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 15, 2021 |
DEFA14A 1 defa14a-2021proxyadditiona.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissio |
|
| March 16, 2021 |
DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Myriad Genetics, Inc. |
|
| March 16, 2021 |
As filed with the Securities and Exchange Commission on March 16, 2021 REGISTRATION NO. |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from July 1, 2020 to December 31, 2020 Commission file number: 0-26642 MYRIAD GENETICS, INC. (Exact nam |
|
| March 16, 2021 |
Non-Employee Director Compensation Policy+ MYRIAD GENETICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective: Fiscal Year 2021) The following is a description of the standard compensation arrangements under which the non-employee directors of Myriad Genetics, Inc. (the ?Company,? ?our? or ?we?) are compensated for their service as directors of the Company, including as members of the various committees of our Board of Directors (t |
|
| March 2, 2021 |
SEC FILE NUMBER 000-26642 CUSIP NUMBER 62855J104 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 23, 2021 |
Myriad Genetics December 2020 Quarterly Earnings February 23, 2021 ?2021 Myriad Genetics, Inc. |
|
| February 23, 2021 |
Exhibit 10.1 AMENDMENT NO. 3 dated as of February 22, 2021 to CREDIT AGREEMENT Dated as of December 23, 2016 THIS AMENDMENT NO. 3 (?Amendment?), dated as of February 22, 2021 (the ?Effective Date?), is entered into by and among MYRIAD GENETICS, INC., a Delaware corporation (the ?Borrower?), the Lenders party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent (the ?Administrative Agent? |
|
| February 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2021 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| February 23, 2021 |
Exhibit 99.1 News Release Media Contact: Jared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 [email protected] [email protected] Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan Highlights: ?Revenue of $154.6 million up 6% sequentially in quarter ended Dec. 31, 2020 ?GAAP Earnings per share (EPS) of ($0.59 |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 Myriad Genetics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to which the Sc |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Myriad Genetics, Inc (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 62855J104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 16, 2021 |
Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| February 16, 2021 |
Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E. |
|
| February 16, 2021 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 16, 2021 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Myriad Genetics Inc. Title of Class of Securities: Common Stock CUSIP Number: 62855J104 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| December 7, 2020 |
2017 Employee, Director and Consultant Equity Incentive Plan, as amended+ Exhibit 10.1 MYRIAD GENETICS, INC. 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN AS AMENDED (December 4, 2020) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended, have the following meanings: Administrator means the Boa |
|
| December 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2020 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 9, 2020 |
myriadearningsslidesfina Myriad Genetics Quarterly Report Ending September 2020 November 9, 2020 Forward looking statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. |
|
| November 9, 2020 |
Executive Employment Agreement between the Registrant and Paul J. Diaz dated July 24, 2020+ Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), made and entered into this 24 day of July, 2020 (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Paul J. Diaz (“Executive”). WHEREAS, the Company wishes to employ Executive as its President and Chief Executive Officer; WHEREAS, Executive repres |
|
| November 9, 2020 |
Exhibit 10.2 MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Performance-Based) 1.Name of Participant: Paul J. Diaz 2.Grant Date: October 8, 2020 3.Vesting Start Date: October 8, 2020 4.Number of Restricted Stock Units (“RSUs”) Awarded: 298,954 5.Vesting Schedule: This Award shall be earned and vest as follows provided (except as otherwise set forth below) the Participant is an Employee |
|
| November 9, 2020 |
Restricted Stock Unit Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+ Exhibit 10.3 MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Time-Based) 1.Name of Participant: Paul J. Diaz 2.Grant Date: August 13, 2020 3.Vesting Start Date: August 13, 2020 4.Number of Restricted Stock Units (“RSUs”) Awarded: 298,954 5.Vesting Schedule: This Award shall vest as follows provided (except as otherwise set forth below) the Participant is an Employee of the Company or of |
|
| November 9, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 9, 2020 |
Form of Separation and Release Agreement between the Registrant and Paul J. Diaz+ Exhibit 10.6 FORM OF SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (the “Agreement”), dated as of [●], is entered into between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”), and [●] (“Executive”) (Executive, together with the Company, the “Parties” and each a “Party”). WHEREAS, Executive served as the [●] of the C |
|
| November 9, 2020 |
Non-Qualified Stock Option Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+ Exhibit 10.5 MYRIAD GENETICS, INC. NON-QUALIFIED STOCK OPTION GRANT NOTICE (Time-Based) 1. Name of Participant: Paul J. Diaz 2. Date of Option Grant: August 13, 2020 3. Maximum Number of Shares for which this Option is exercisable: 342,040 4. Exercise (purchase) price per share: $13.38 5. Option Expiration Date: August 13, 2027 6. Vesting Start Date: This option shall vest and become exercisable a |
|
| November 9, 2020 |
Exhibit 99.1 News Release Media Contact: Jared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 [email protected] [email protected] Myriad Genetics Delivers 56% Sequential Increase in Quarterly Revenue; Test Volumes Reach 90% of Pre-COVID-19 Level at End of Quarter Highlights: •Revenue of $145.2 million up 56% sequentially in quarter ended Sept. 30, 2020 •GAAP operating in |
|
| November 9, 2020 |
Exhibit 10.4 MYRIAD GENETICS, INC. NON-QUALIFIED STOCK OPTION GRANT NOTICE (Performance-Based) 1. Name of Participant: Paul J. Diaz 2. Date of Option Grant: August 13, 2020 3. Maximum Number of Shares for which this Option is exercisable: 339,088 4. Exercise (purchase) price per share: $13.38 5. Option Expiration Date: August 13, 2027 6. Vesting Start Date: This option shall vest and become exerci |
|
| November 9, 2020 |
Regulation FD Disclosure, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 15, 2020 |
EX-3.1 Exhibit 3.1 MYRIAD GENETICS, INC. RESTATED BY-LAWS (Amended and Restated October 9, 2020) ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such tim |
|
| October 15, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement 1 ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| October 15, 2020 |
2017 Employee, Director and Consultant Equity Incentive Plan, as amended as of October 9, 2020 EX-10.2 Exhibit 10.2 MYRIAD GENETICS, INC. 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN AS AMENDED (October 9, 2020) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Myriad Genetics, Inc. 2017 Employee, Director and Consultant Equity Incentive Plan, as amended, have the following meanings: Administrator means |
|
| October 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2020 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 15, 2020 |
Form of Severance and Change in Control Agreement+ EX-10.1 Exhibit 10.1 SEVERANCE AND CHANGE IN CONTROL AGREEMENT This Severance and Change in Control Agreement (the “Agreement”) is made and entered into [DATE] (the “Effective Date”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and [NAME] (“Employee”). WHEREAS, Employee is currently employed by the Company under the terms of a separate employment agreement (the “E |
|
| October 15, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| October 15, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 15, 2020 |
EX-99.1 Exhibit 99.1 News Release Media Contact: Jared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 [email protected] [email protected] Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder Interests SALT LAKE CITY, Oct. 15, 2020 – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diag |
|
| October 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2020 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission |
|
| September 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission |
|
| September 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2020 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission F |
|
| September 10, 2020 |
EX-99.1 Exhibit 99.1 News Release Media Contact: Jared Maxwell (801) 505-5027 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected] Myriad Genetics Expands Board of Directors with New Member Rashmi Kumar Elected to Myriad’s Board of Directors. SALT LAKE CITY, Sept. 10, 2020 – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecu |
|
| August 14, 2020 |
Form of Restricted Stock Unit Agreement EX-99.3 Exhibit 99.3 MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Time-Based) 1. Name of Participant: Paul J. Diaz 2. Grant Date: August 13, 2020 3. Vesting Start Date: August 13, 2020 4. Number of Restricted Stock Units (“RSUs”) Awarded: [ ] 5. Vesting Schedule: This Award shall vest as follows provided (except as otherwise set forth below) the Participant is an Employee of the Compa |
|
| August 14, 2020 |
Form of Performance-Based Non-Qualified Stock Option Agreement EX-99.2 Exhibit 99.2 MYRIAD GENETICS, INC. NON-QUALIFIED STOCK OPTION GRANT NOTICE (Performance-Based) 1. Name of Participant: Paul J. Diaz 2. Date of Option Grant: August 13, 2020 3. Maximum Number of Shares for which this Option is exercisable: [ ] 4. Exercise (purchase) price per share: $[ ] 5. Option Expiration Date: August 13, 2027 6. Vesting Start Date: This option shall vest and become exer |
|
| August 14, 2020 |
S-8 As filed with the Securities and Exchange Commission on August 13, 2020 REGISTRATION NO. |
|
| August 14, 2020 |
Form of Performance-Based Restricted Stock Unit Agreement EX-99.4 Exhibit 99.4 MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AWARD NOTICE (Performance-Based) 1. Name of Participant: Paul J. Diaz 2. Grant Date: August [], 2020 3. Vesting Start Date: August [], 2020 4. Number of Restricted Stock Units (“RSUs”) Awarded: [] 5. Vesting Schedule: This Award shall be earned and vest as follows provided (except as otherwise set forth below) the Participant is an E |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 14, 2020 |
Myriad Genetics Announces Inducement Awards EX-99.1 Exhibit 99.1 News Release Media Contact: Jared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 [email protected] [email protected] Myriad Genetics Announces Inducement Awards SALT LAKE CITY, August 14, 2020 – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced that in con |
|
| August 14, 2020 |
Form of Non-Qualified Stock Option Agreement EX-99.1 Exhibit 99.1 MYRIAD GENETICS, INC. NON-QUALIFIED STOCK OPTION GRANT NOTICE (Time-Based) 1. Name of Participant: Paul J. Diaz 2. Date of Option Grant: August 13, 2020 3. Maximum Number of Shares for which this Option is exercisable: [ ] 4. Exercise (purchase) price per share: $[ ] 5. Option Expiration Date: August 13, 2027 6. Vesting Start Date: This option shall vest and become exercisable |
|
| August 13, 2020 |
pl To be more UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-26642 MYRIAD GE |
|
| August 13, 2020 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 0-26642 87-0494517 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 13, 2020 |
Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan+ Exhibit 10.11 MYRIAD GENETICS, INC. RESTRICTED STOCK UNIT AGREEMENT - INCORPORATED TERMS AND CONDITIONS AGREEMENT made as of the date of grant set forth in the Restricted Stock Unit Award Grant Notice between MYRIAD GENETICS, INC. (the “Company”), a Delaware corporation, and the individual whose name appears on the Restricted Stock Unit Award Grant Notice (the “Participant”). WHEREAS, the Company |
|
| August 13, 2020 |
List of Subsidiaries of the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES OF MYRIAD GENETICS, INC. Company Name Jurisdiction of Incorporation Myriad Genetic Laboratories, Inc.1 Delaware Assurex Health, Inc.1 Delaware Myriad RBM, Inc.1 Delaware Crescendo Bioscience, Inc.1 Delaware Myriad Women’s Health, Inc1 Delaware Myriad GmbH3 Germany Myriad Services GmbH2 Germany Myriad Genetics Espana SL1 Spain Myriad Genetics SAS2 France Myriad Gen |
|
| August 13, 2020 |
EX-99.1 Exhibit 99.1 News Release Media Contact: Jared Maxwell Investor Contact: Scott Gleason (801) 505-5027 (801) 584-1143 [email protected] [email protected] Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of Directors SALT LAKE CITY, August 13, 2020 – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in |
|
| August 13, 2020 |
Myriad Genetics Fiscal Fourth-Quarter 2020 Earnings Call August 13, 2020 Exhibit 99. |
